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Retinopathy of prematurity (ROP), a signiﬁcant morbidity in prematurely born infants, is
the most common cause of visual impairment and blindness in children and persists till
adulthood. Strict control of oxygen therapy and prevention of intermittent hypoxia are the
keys in the prevention of ROP, but pharmacologic interventions have decreased risk of ROP.
Various drug classes such as methylxanthines (caffeine), VEGF inhibitors, antioxidants, and
others have decreased ROP occurrence. The timing of pharmacologic intervention remains
unsettled, but early prevention rather than controlling disease progression may be
preferred. These drugs act through different mechanisms, and synergistic approaches
should be considered to maximize efﬁcacy and safety.
& 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Retinopathy of prematurity (ROP) is a developmental vascular
disorder characterized by abnormal growth of retinal blood
vessels in the incompletely vascularized retina of extremely
low gestational age neonates (ELGANs) who areo1250 g,o28
weeks gestation.1–3 In the United States, ROP afﬂicts about
16,000 ELGANs annually1 and remains the third leading cause
of childhood blindness (14%) with much higher rates in
developing countries.5 Incomplete retinal vascularization
due to prematurity and oxygen are key factors in ROP;
however, the etiology of this “new” form of ROP is multi-
variate and complex and involves hypersensitivity of the
immature retina to changes in oxygen.4,6,76
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In humans, the retina develops in utero where tissue oxygen
is low.7 Vascular precursor cells are laid from 12 to 21 weeks
gestational age creating a scaffold for future vessel develop-
ment. The vessels emerge from the optic disk and follow a
VEGF template established by astrocytes which populate the
retina before the vessels.8 Angiogenesis begins at approxi-
mately 16–17 weeks gestational age, with new vessels bud-
ding from existing vessels. The metabolic demands of the
developing retina exceed the oxygen supplied by the choroi-
dal circulation resulting in “physiologic hypoxia,” and thus
stimulate angiogenesis.7 Vasoactive factors, such as insulin-
like growth factor (IGF)-1, vascular endothelial growth factorpen access article under the CC BY-NC-ND license
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derived factors, stimulate new vessel formation. The vessels
reach the nasal ora serrata by 36 weeks and the temporal ora
serrata by 40 weeks. In ELGANs, the retinal vasculature is
immature and thus vulnerable to oxidative damage. Early
studies by Ashton et al.9 demonstrated that exposure to
oxygen causes vaso-obliteration and vasoproliferation when
room air breathing was resumed. Those early studies led to a
two-phase hypothesis of ROP: (1) phase 1 or vaso-obliteration
begins at preterm birth with the transition from an intra-
uterine to extrauterine environment causing a rise in PaO2 of
30–35 mmHg to 55–80 mmHg and loss of placental and
maternal growth factors. During this phase, exposure to
supplemental oxygen, required for treatment of respiratory
distress syndrome, further suppresses retinal growth factors
that are already compromised due to preterm birth and poor
nutrition,10 thus leading to arrest and retraction of the
developing retinal vessels, or vaso-obliteration; and (2) phase
2 or vasoproliferation begins at approximately 32–34 weeks.11
As the infant matures, the avascular retina becomes meta-
bolically active, inducing a second phase, or retinal neo-
vascularization.3 This phase of ROP is driven by hypoxia
and subsequent upregulation of VEGF and IGF-I which leads
to abnormal vascular overgrowth into the vitreous, retinal
hemorrhages, retinal folds, dilated and tortuous posterior
retinal blood vessels, or “Plus” disease, and retinal detach-
ment. ELGANs with chronic lung disease experience numer-
ous alterations in their O2 saturations or apneas.
12,13 Infants
who experience the greatest ﬂuctuations in their PaO2 seem
to be at a higher risk for the development of threshold
ROP.6,13 In these infants with “new” ROP, intermittent hypo-
xia (IH) occurs during supplemental oxygen treatment or
phase 1, thus worsening the outcomes during phase 2.
Indeed, this was demonstrated in a rat model that utilized
brief episodes of hypoxia during hyperoxia, simulating apnea
of prematurity.14–17 The ﬂuctuating oxygen model also shows
a higher incidence of intravitreal neovascularization18 with
corresponding high levels of retinal VEGF19 and vitreous ﬂuid
growth factors.14,15 The pattern of IH may also play a role in
the development of ROP13 and OIR.14–17 Clustering IH episodes
resulted in a more severe form of OIR with increased retinal
hemorrhages, vascular tufts, leaky vessels, vascular tortuos-
ity, and vascular overgrowth, compared to dispersed IH
episodes. This may be due to differences in exposure time
of the retina to hypoxia at a given time point. Clustering
episodes of brief hypoxia or grouping of desaturations with
minimal time for recovery between episodes causes the
retina to remain hypoxic for a longer period of time, thus
leading to a more exaggerated increase in VEGF resulting in
characteristics consistent with “Plus” disease.14 In light of
these new ﬁndings, the phase 1/phase 2 hypothesis of ROP
originally proposed in 1954 by Ashton et al.9 may need to be
redeﬁned with respect to “new” ROP and IH.
Oxygen
Oxygen is the most commonly used drug in neonatal care for
respiratory support.20 The widespread use of unrestricted
oxygen in preterm infants began in the early 1940s in
response to observations that inspired oxygen improved theirregular breathing pattern of premature infants.21,22 This led
to the ﬁrst epidemic of ROP, described in 1942 by Terry.23 and
then known as retrolental ﬁbroplasia or ﬁbroblastic over-
growth behind the crystalline lens. In 1951, it was suggested
that oxygen use was associated with ROP.24 This was con-
ﬁrmed in 1952 in humans25 and later in animals.26 By 1953,
approximately 10,000 infants worldwide were blinded.21 The
ﬁrst multicenter randomized clinical trial to study ROP
started in 1953 and involved 18 centers. The study enrolled
infants o1500 g in two arms: (1) FiO2 Z 50% for 28 days and
(2) FiO2 o 50%. In 1954, one of the centers reported that
blindness was prevented if oxygen did not exceed 40%.
However, 6 years later, review of autopsies revealed that
curtailed use of oxygen increased the incidence of mortality
such that for every eye sight gained, 16 lives were lost.27
Despite the introduction of transcutaneous oxygen monitor-
ing and pulse oximetry in the 1960s–1980s, and many non-
randomized and randomized clinical trials, the optimum
range of oxygenation in preterm infants remains elusive
and controversial. The phase 1 (hyperoxia)/phase 2 (hypoxia)
hypothesis of ROP led to the premise that administration of
oxygen during phase 2 would increase tissue oxygen,
decrease VEGF, and curtail vessel overgrowth. This hypoth-
esis was tested in the Supplemental Therapeutic Oxygen for
Prethreshold Retinopathy of Prematurity (STOP-ROP)
randomized clinical trial in 2000.28 The study randomized
649 infants with prethreshold ROP and O2 saturationo94% at
35 weeks to oxygen saturation targets of 89–95% or 96–99%.
The STOP-ROP study failed to decrease progression of the
disease or reduce the number of infants requiring peripheral
ablative surgery and showed no differences in the develop-
ment of threshold ROP. ELGANs experience continuous ﬂuc-
tuations in arterial O2 saturation; therefore, increasing
inspired oxygen may not be an appropriate approach.29,30
Instead, low and stable oxygen therapy may be more bene-
ﬁcial.2 The Australian Beneﬁts of Oxygen Saturation Target-
ing (BOOST) randomized, double-blind, multicenter trial
involving 358 preterm infants, kept the saturation ranges at
91–94% or 95–98%. The incidence of severe ROP was compa-
rable between the groups.31 Five large multicenter, masked,
randomized, control trials (collectively known as The Neo-
natal Oxygen Prospective Meta-Analysis or NeOPRoM Collab-
oration) enrolled approximately 5000 ELGANs o28 weeks,
compared 85–89% versus 91–95%. In the United States, the
Surfactant Positive Pressure and Pulse Oximetry (SUPPORT)
trial reported that SpO2 levels of 85–89% was associated with
increased mortality and a higher incidence of severe ROP was
found in the 91–95% group.32 This was reﬂected in the BOOST
II trial (Australia, New Zealand, and United Kingdom) after
interim analysis, and enrollment was stopped.33 The Cana-
dian Oxygen Trial (COT) reported no difference in mortality or
severe ROP.34 A recent meta-analysis of all published
randomized trials evaluating the effect of restricted versus
liberal oxygen exposure in preterm infants shows no differ-
ence in ROP.35 After over 70 years of oxygen use, and despite
large multicenter, randomized clinical trials, there is still no
consensus regarding optimal oxygen therapy for ELGANs.
Oxygen remains the most commonly used drug in neonatal
intensive care units worldwide36 and the incidence of severe
ROP has not appreciably declined.
S E M I N A R S I N P E R I N A T O L O G Y 4 0 ( 2 0 1 6 ) 1 8 9 – 2 0 2 191Pharmacologic interventions in ROP
In addition to better control of oxygen therapy, numerous
pharmacologic interventions have been tried, and some
appears promising for the prevention of ROP and stopping
its progression. These pharmacologic agents are discussed.
Antioxidants
Oxygen used in excess has damaging effects particularly
when used in ELGANs. In normal respiration, oxygen is
reduced in the mitochondria to two molecules of water
during the process of aerobic energy metabolism, or oxidative
phosphorylation (OXPHOS), which produces more than 90%
of our cellular energy.37 During OXPHOS, reactive oxygen
species (ROS) are produced as a byproduct. ROS are highly
reactive chemical molecules that react with lipids to initiate
lipid peroxidation and DNA damage.38 Major ROS produced in
the mitochondria are superoxide anion, hydrogen peroxide
(H2O2), hydroxyl radical, and hydroperoxyl radical. Reactive
nitrogen species (RNS) such as nitric oxide (NO), nitrogen
dioxide (NO2), dinitrogen trioxide (N2O3), and peroxynitrite,
are also produced. The primary endogenous scavengers of
ROS, or antioxidants, are superoxide dismutase (SOD), cata-
lase, and glutathione peroxidase (Gpx). SOD acts on super-
oxide anion to produce hydrogen peroxide (H2O2), catalase
converts H2O2 to water, and Gpx detoxiﬁes peroxides and
hydroperoxides. Other antioxidants include peroxiredoxins
(which catabolize H2O2 to water), peroxiredoxin, heme oxy-
genase, glutaredoxin and thioredoxin, and nonenzymatic
agents such as β-carotene, retinol, vitamin C, and vitamin E.
When endogenous antioxidant systems are inadequate or
overwhelmed by ROS, many pathologies including hypoxia/
reperfusion injury and ROP develop. The retina is rich in
mitochondria and has a high rate of OXPHOS, thus rendering
it a target for ROS and oxidative damage.39,40 Excessive ROS
production contributes to mitochondrial damage and vascu-
lar dysfunction, particularly in ELGANs with immature anti-
oxidant systems.41–43 Therefore, many investigators tested
the hypothesis that antioxidants are beneﬁcial for treatment
and/or prevention of ROP.
Vitamin E was the ﬁrst antioxidant to be used for treatment
and prevention of ROP.44 Several later trials of supplementing
preterm infants with vitamin E for preventing or limiting ROP
have been conducted with conﬂicting results.45–51 A random-
ized trial of 755 VLBW infants found no signiﬁcant decrease of
severe ROP although the progression frommoderate to severe
ROP was less frequent following vitamin E treatment.47
Phelps et al.52 and Rosenbaum et al.53 found increased retinal
hemorrhages and an increased rate of grades 3 and 4 IVH in
the vitamin E group. Two meta-analyses reported beneﬁcial
effects of Vitamin E for reducing the risk of ROP and blind-
ness. The earlier report analyzed six clinical trials and found
a 52% reduction in the incidence of stage 3þ ROP.54 The later
report analyzed 26 randomized clinical trials and a reduction
in severe ROP and blindness.55 A third report found no effect
at all.56 In this report, the authors analyzed nine randomized
controlled trials and concluded that not more than about 4%
of all very low-birthweight infants are likely to beneﬁt fromroutine vitamin E supplementation. Vitamin E was the most
commonly used antioxidant for ROP spanning over 4 decades.
Its use has now been largely abandoned secondary to
increased risks of morbidity with no conclusive evidence for
protection against severe ROP.
Other antioxidants used to treat/prevent ROP include: D-
penicillamine (DPA) an antioxidant and suppressor of VEGF
bioavailability.57 DPA was introduced to prevent ROP in the
1980s. In a prospective controlled trial, DPA was administered
to preterm infants at 26–35 weeks gestation and found to be
effective for ROP with no serious adverse effects58 and at 1-
year follow-up.59 Later trials refuted those ﬁndings60,61; super-
oxide dismutase (SOD) dismutates the extremely toxic super-
oxide anion into H2O2 and H2O. SOD is the ﬁrst line of defense
against oxidative stress in the mitochondria, with MnSOD
located in the inner mitochondrial matrix. A multicenter trial
of intratracheal rhSOD showed a reduction in severe ROP
above stage 2 in rhSOD-treated infants born at o25 weeks62;
lutein and zeaxanthin are antioxidants in the eye. A single-
center, double-blind randomized controlled trial comparing
lutein administration versus placebo, showed no differences
in the incidence of ROP at any stage.63 These ﬁndings were
later conﬁrmed64,65; vitamin A is one of the most important
micronutrients necessary for growth and differentiation of
tissues.66 Vitamin A supplementation reduces infant mortal-
ity.67 Retinal vitamin A allows adequate rhodopsin availabil-
ity for phototransduction and protects the photoreceptors
from the harmful effects of hypoxia and hyperoxia.68 Studies
show a trend for decreased incidence of threshold ROP in
ELBW infants treated with 10,000 IU intramuscular vitamin A
three times a week (0%) compared with 16% in those who
received half this dose.69 A recent double-blind, randomized
controlled trial of early high-dose intramuscular vitamin A
supplementation for infants at risk of ROP showed improved
retinal function at 36 weeks PMA.68 A meta-analysis of the
three studies suggests a trend toward reduced incidence of
ROP in vitamin A supplemented infants.70 Although promis-
ing, there is a paucity of studies examining the beneﬁts of
vitamin A for severe ROP. Considering its antioxidant proper-
ties and possible beneﬁcial effects on the photoreceptors,
further studies are warranted, and allopurinol is a xanthine
oxidase and superoxide anion inhibitor. A randomized, con-
trolled, clinical trial involving 400 preterm infants who
received either allopurinol or placebo showed no beneﬁt.71
Cyclooxygenase inhibitors
In preterm infants who are exposed to supraphysiologic
levels of oxygen and have compromised antioxidant systems,
the imbalance of oxidant/antioxidants in favor of oxidants
lead to oxidative stress and activation of proinﬂammatory
mediators, including prostanoids.72,73 The primary pathway
through which prostanoids are activated is through arach-
idonic acid (AA), a long-chain polyunsaturated fatty acids
released from phospholipids through the action of phospho-
lipase A1 (PLA2).
74 AA is the precursor of the eicosanoids,
including prostanoids, through the cyclooxygenase (COX)
enzyme, and leukotrienes, through the lipoxygenase (LOX)
pathway. The two main COX isoforms are the consti-
tutively expressed COX-1, responsible for maintaining basal
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absent and is induced in inﬂammation.75,76 Both isoforms
transform AA into prostaglandin H2, which is then trans-
formed by synthases into prostaglandins (PGs) and throm-
boxanes. A third isoform, COX-3 was identiﬁed in 200277 as a
variant of COX-1. This variant is more sensitive to acetami-
nophen.78 The role of prostanoids in ROP has been demon-
strated.73,79–81 Other prostanoid compounds, the F-
isoprostanes, are generated by lipid peroxidation of AA,
independent of COX.82,83 One of these isomers, 8-epi-
prostaglandinF2α (8-epi-PGF2α), is a potent mitogen and con-
strictor of vascular smooth muscle and is highly correlated
with oxidative stress.83 Studies have demonstrated that 8-
epi-PGF2α is functionally linked to, and activates the throm-
boxane A2 (TxA2) receptor
84 and may be involved in retinal
vasoconstriction and ischemic retinopathies.85 The impor-
tance of the prostanoid cascade in ROP and the role of COX-2
in inﬂammation led to the premise that COX inhibition could
have potential beneﬁts. Nonselective COX inhibitors, such as
indomethacin and ibuprofen, improve OIR and ocular bio-
markers of angiogenesis in animal models.86–90 However,
there are only two clinical studies involving the use of COX
inhibitors for prevention of ROP. One controlled study admin-
istered topical ketorolac (a nonselective COX inhibitor) to 59
infants (o30 weeks gestation, o1250 gbirth weight) every 8 h
in each eye compared to 53 untreated preterm infants.
Ketorolac reduced the risk of developing severe ROP with no
signiﬁcant adverse side effects.91 A later study of 47 preterm
infants (o29 weeks, o1000 g) who receive ketorolac in one
eye and placebo in the other eye showed that two infants did
not develop ROP, six showed different ROP staging between
the two eyes, four of which had a better outcome in the eye
receiving ketorolac and no signiﬁcant treatment-related side
effects occurred.92 Dexamethasone is a selective COX-2
inhibitor with anti-inﬂammatory effects that has been dem-
onstrated to reduce the incidence of ROP.93,94 However, its
use is associated with signiﬁcant side effects,95–100 and its
efﬁcacy in preventing ROP is controversial. Despite over-
whelming evidence for the role of COX metabolites in
oxidative stress and inﬂammation, only one prospective
randomized, controlled multicenter clinical trial to investi-
gate the beneﬁts of COX inhibitors for prevention of ROP has
been initiated and is currently underway (Aranda JV, Clin-
icaltrials.gov Identiﬁer: NCT02344225).Inositol
Inositol is a nonglucose carbohydrate that is present in high
amounts in the umbilical cord and maternal serum at
term.101 Inositol is also present at high concentrations in
human breast milk, particularly colostrum suggesting an
importance for postnatal growth.102 In 1992, Hallman
et al.103 showed a reduction in ROP in inositol-treated infants
(13%) versus placebo (26%), and none of the infants given
inositol had stage 4 disease compared to seven in the placebo
group. These ﬁndings were later conﬁrmed by Friedman
et al.104 In 2015, a meta-analysis of four clinical trials showed
reduced stage 3 ROP in two of the four trials.105 A large size
multicenter, randomized, controlled trial is currently ongoingto further investigate the beneﬁts of inositol for ROP (Clin-
icaltrials.gov Identiﬁer: NCT01954082).Propranolol
Propranolol is one of the newest proposed treatments for ROP
despite weak and contradictory animal preclinical data.
Propranalol is a nonselective β-adrenoreceptor blocker shown
to reduce the growth of infantile capillary haemangiomas.106
The mechanism of action is likely due to suppression of
VEGF. Studies have shown that polymorphisms of the β-
adrenergic receptor in many black infants may be responsible
for the lower incidence of ROP.107 Clinical trials have shown
reduction in the incidence of ROP with oral propranolol with
few side effects.108–110 Clinical trials in Israel and Italy are
being conducted to evaluate efﬁcacy and safety of this beta
blocker for ROP prevention in preterm neonates (Clinical-
Trials.Gov: NCT01238471, NCT02014454, and NCT02504944).
One Italian Trial using propranolol eye drops of 0.5 mg/kg
oral, every 6 h was discontinued due to serious adverse
effects attributed to the pharmacologic actions of propranolol
such as severe hypotension, bradycardia, or bronchospasm
(ClinicalTrials.Gov NCT01079715).Caffeine
Caffeine is the most widely used drug worldwide.111 It is a
methylxanthine that acts to antagonize adenosine receptors
and block the release of endogenous adenosine. Caffeine also
stimulates dopaminergic activity by removing the negative
modulatory effects of adenosine at dopamine receptors.112
Caffeine was ﬁrst demonstrated to be effective for treatment
of apnea of prematurity (AOP) in the 1970s by Aranda et al.113
After over 40 years, caffeine is now the drug of choice for AOP.
It is one of the most commonly prescribed drugs for use in
ELGANs.114,115 It is a respiratory stimulant in ELGANs and is
effective for reducing the duration of mechanical ventila-
tion.116 The Caffeine for Apnea of Prematurity (CAP) trial
found that caffeine was also beneﬁcial for reducing the
incidence of bronchopulmonary dysplasia (BPD), improving
long-term neurodevelopmental outcome, and reducing the
incidence of severe ROP.117 The mechanism of caffeine effects
on severe ROP remains to be determined, but may involve
effects on regulators of angiogenesis such as VEGF, sonic
hedgehog matrix metalloproteinases (MMPs), and oxidative
stress.118–121 Additionally, caffeine potentiates the anti-
inﬂammatory effects of COX inhibitors in activated microglia
which may also occur in the retina.122 Caffeine has been used
in combination with non-steroidal anti-inﬂammatory drugs
(NSAIDs) for many decades to enhance their analgesic effects,
suggesting that caffeine may be an effective adjuvant to
NSAIDs.122–124 Due to its signiﬁcant impact on major acute
neonatal morbidities including AOP, BPD, PDA, and ROP,
caffeine is now recognized as the “wonder drug in neonatol-
ogy”125 and the “silver bullet in neonatology.”126 Notwith-
standing, only one prospective randomized, controlled
multicenter clinical trials to investigate the beneﬁts of caf-
feine for prevention of ROP has been initiated (Aranda JV,
Clinicaltrials.gov Identiﬁer: NCT02344225).
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ROP is characterized by the formation of new and aberrant
retinal vasculature, suggesting that angiogenic factors play a
major role. The role of angiogenic factors in retinal develop-
ment was ﬁrst hypothesized 1948.127 In 1983, Senger et al.128
discovered an angiogenic growth factor present in tumor cells
which he named vascular permeability factor due to its
ability to induce vascular leakage. In 1989, Ferrara and
Henzel129 identiﬁed, puriﬁed, and characterized a heparin-
binding angiogenic growth factor speciﬁc for vascular endo-
thelial cells which they named VEGF. Several other angio-
genic factors have been identiﬁed, including ﬁbroblast growth
factor (FGF), platelet-derived growth factor (PDGF), transform-
ing growth factor (TGF), the angiopoietin family, insulin-like
growth factor (IGF), and the Ephrin family, all of which work
together to promote functional vascular systems.130 VEGF is a
vascular permeability factor. Consistent with this character-
istic is its ability to induce the expression of plasminogen
activators and MMPs to increase vascular permeability131,132
which may be the ﬁrst step in angiogenesis.133 It is now widely
accepted that the VEGF family is the most potent inducer of
angiogenesis and ROP. Levels of VEGF in the vitreous humor
correlate with the degree of neovascularization.134,135 Plasma
levels of preterm infants in the ﬁrst week of life were found to
be low (48 pg/mL) compared to term infants (200–450 pg/mL)
and adults (10–110 pg/mL).136 VEGF levels in the aqueous
humor of stage 4 (1109 pg/mL) and stage 5 (3520 pg/mL) eyes
were considerably higher than control eyes (158 pg/mL).137
Infants with stage 4 ROP had elevated VEGF levels in the
subretinal ﬂuid and decreased levels in stage 5.138 Induction
of VEGF is also associated with generation of ROS, inﬂamma-
tory cytokines and prostanoids, possibly via inducible COX-
2.139–141 VEGF is now considered the most important target for
therapeutic interventions for prevention of severe ROP.
VEGF inhibitors
Several anti-VEGF drugs have been developed. The ﬁrst anti-
VEGF drug to be approved by the FDA for cancer use was
bevacizumab (Avastin).142 Bevacizumab is a recombinant
humanized antibody that binds all forms of VEGF-A.
Although it is used off-label, it is not formulated for use
within the eye.142 However, off-label use by ophthalmologists
demonstrated that Avastin was beneﬁcial when injected into
the vitreous of adults with macular degeneration. Later, a
truncated form of Avastin called ranibizumab (Lucentis) was
FDA-approved for ocular use. The ﬁrst FDA-approved drug for
use in ocular neovascularization was pegaptanib (Macugen).
Aﬂibercept (Eyelea), a human soluble VEGF receptor, which
acts as a decoy to trap VEGF, was recently FDA-approved for
ocular use. Bevacizumab is the ﬁrst anti-VEGF drug to be used
for treatment of ROP in 2007.143 Since then, many single-
center trials and case reports have been published making
bevacizumab the most widely used drug for treatment of
severe ROP. The ﬁrst meta-analysis of bevacizumab use for
ROP was published in 2009.144 The authors analyzed all case
reports, and retrospective and prospective trials in peer-
reviewed journals reporting the use of bevacizumab in ROP,
including nine articles, six case reports, one case series, andtwo retrospective studies of 48 infants administered doses
from 0.4 to 1.25 mg and cautioned against potential systemic
complications and long-term effects of intravitreal bevacizu-
mab in preterm infants. From 2007 to 2009, all investigators
reported favorable outcomes with bevacizumab use in ROP.
However, the ﬁrst report of adverse effects was published in
2010 demonstrating choroidal ruptures at 10 weeks post-
treatment with laser.145 Other reports of adverse events
included vitreous or preretinal hemorrhage,146 delayed bilat-
eral retinal detachments at 1 month post-treatment,147 and
retinal detachment.148 The ﬁrst multicenter randomized,
controlled trial was the BEAT-ROP study which demonstrated
an advantage of intravitreal bevacizumab over laser therapy
for zone I or zone II with stage 3þ ROP by improving
structural outcomes, decreasing recurrence, and allowing
continued development of peripheral retina.149 In the BEAT-
ROP study, however, assessments of local and systemic
safety proﬁle was not determined and follow-up was only
54 weeks postmenstrual age. Moshfeghi and Berrocal150
estimated that 47.7% of recurrences would have occurred
after the 54 weeks. This was demonstrated by Hu et al.151
Studies have since tried to address safety of intravitreal
bevacizumab use in ROP and demonstrated numerous acute
and latent retinal adverse effects.151–168 Interestingly, serum
concentrations of bevacizumab concurrent with suppressed
systemic VEGF levels lasted up to 60 days post-intravitreal
administration,169–172 and the levels were signiﬁcantly lower
than previously reported in preterm infants.173 These reports
demonstrate that bevacizumab escapes from the eye into the
systemic circulation and has long-lasting effects on systemic
VEGF levels in infants with ROP. A recent meta-analysis of
eight prospective studies of 278 eyes of ROP infants and 15
retrospective studies involving 385 eyes of ROP infants
treated with intravitreal bevacizumab showed reoccurrence
and acceleration of ﬁbrous traction.174 Other anti-VEGF drugs
used in ROP include ranibizumab which has a shorter half-life
with the potential for decreased systemic toxicity. Treatment
with ranibizumab was also associated with signiﬁcant
adverse outcomes.147,175,176 Combination treatment of intra-
vitreal pegaptanib or bevacizumab injection and laser photo-
coagulation showed signiﬁcant beneﬁts in the management
of stage 3þ ROP.177,178 Evidence now exist that intravitreal
administration of anti-VEGF drugs can have prolonged sup-
pressive effects on systemic VEGF in ELGANs. Considering the
role of VEGF in the development of vital organs, more
randomized, controlled multicenter trials should be con-
ducted to evaluate dose–response effects and long-term
safety proﬁles in this vulnerable population.179–186
Insulin-like growth factor (IGF)-1
Although VEGF plays an important role in the development of
ROP, its inhibition does not completely prevent ROP. Another
growth factor that is currently being studied for prevention of
ROP is IGF-1. IGF-1 inﬂuences endothelial cell growth and
angiogenesis,187,188 and plays a critical role in the retinal
vasculature development through its interaction with VEGF,
acting as a permissive factor for maximum VEGF stimulation
of angiogenesis.189,190 Mean IGF-1 level has been shown as
signiﬁcantly and proportionately lower in postmenstrual age
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Work by Hellstrom et al.191,194 have demonstrated that preterm
infants who do not develop ROP have signiﬁcantly higher
circulating levels of IGF-I than those who do. Serum IGF-1 levels
to predict ROP has been shown to be a reliable prognostic tool by
some studies195,196 but not others.197–199 Only one small single-
center clinical trial of Premiplex (rhIGF1/rhIGFBP3) pharmacoki-
netics in ﬁve preterm infants was conducted. None of the
infants developed severe ROP.200 A clinical trial to determine
the dose of hIGF-1/rhIGFBP-3 given as a Continuous Infusion, to
establish and maintain physiologic levels of serum IGF-1 Levels
to prevent ROP is ongoing (ClinTrials.gov NCT01096784).
Polyunsaturated fatty acids (PUFAs)
Omega-6 and omega-3 PUFAs are essential fatty acids that
are important for normal growth, vision, and neurodevelop-
ment. Omega-6 PUFAs are formed from linolenic acid (LA)
which is converted by desaturation and chain elongation to
arachidonic acid (AA), the precursor to eicosanoids (prosta-
glandins, thromboxane, and leukotrienes).201 Omega-3 PUFAs
are formed from alpha-linolenic acid (ALA) which is desatu-
rated and chain elongated to docosahexaenoic acid (DHA).202
PUFAs are important components of the phospholipid bilayer
of cell membranes and contributes to cell structural integrity
and function.203 Deﬁciency of AA and DHA in the membrane
alters the physical properties of the lipid bilayer and induces
vascular leakage.204 It is well established that omega-3 PUFAs
play a key role in the protection against oxidative stress and
inﬂammation. Among the beneﬁts of omega-3 PUFAs is the
ability to regulate eicosanoid metabolism. COX catalyzes the
initial oxygenation of PUFAs to produce prostaglandin H
(PGH2), a short-lived intermediate, which is further metabo-
lized to prostanoids.205 DHA and its precursor, eicosapentae-
noic acid (EPA), reduce the formation of COX-2-derived
PGE2,
206 a metabolite of omega-6 PUFA-derived AA. COX-2-
derived PGE2 increases VEGF-stimulated invasiveness and
angiogenesis through NF-κB.207 There is compelling evidence
that EPA could function as a selective COX-2 inhibitor.207–209
In the retina, PUFAs accumulate rapidly during the later
stages of gestation and early postnatal life.210,211 The retina
contains the highest concentration of DHA of all tissues
where it is cytoprotective and plays a key role in angiogenic
regulation and neuroprotection.212 Administration of ﬁsh oil
to preterm infants from the ﬁrst day of life showed a signiﬁ-
cantly lower incidence and severity of ROP and risk of laser
therapy in the treated group.213–215 However, two meta-
analyses examined the potential beneﬁts of lipid administra-
tion and found no signiﬁcant beneﬁts for the outcome of
ROP.216,217 Treatment with omega-3 fatty acids appears to be
a promising therapy for prevention and/or treatment of ROP,
but there is a paucity of multicenter randomized clinical trials.Drugs associated with incidence of ROP
Surfactant
One of the earlier drugs found to be associated with ROP is
surfactant, despite conﬂicting reports. In the 1990s, therewere three report of a higher occurrence of ROP with surfac-
tant use.218–220 However, comparing the two commonly used
surfactants at that time, Exosurf and Survanta, there was a
higher occurrence of ROP in the Exosurf group.220 A later
meta-analysis involving 10 randomized clinical trials and
over 2000 preterm infants conﬁrmed those ﬁndings of a
higher risk for ROP with Exosurf.221 Numerous other clinical
trials and meta-analyses showed no increased risk for ROP
with surfactant therapy.
Erythropoietin (Epo) is routinely used to treat anemia of
prematurity. Epo is a glycoprotein hormone, expressed
mainly in the kidney and fetal liver. It is highly responsive
to HIF-1α and hypoxia and is the main regulator of red blood
cell production. Many observational and retrospective studies
have reported that Epo is associated with an increased risk of
ROP,222–228 while other studies report no risk.229–231 Early
meta-analyses involving 23 studies and 2074 preterm infants
in 18 countries showed a signiﬁcant increase in the risk of
stage 43 ROP in the Epo group.232 An update in 2014 showed
no signiﬁcant increase in the rate of stageZ3 ROP for studies
that initiated EPO treatment at less than 8 days of age.233
Another meta-analysis done in 2015 also concluded that
there were no differences in the incidence of stage Z3 ROP
with Epo use.234 Clearly, there are major conﬂicts regarding
the role of Epo in the development of ROP, and the reasons
for this remain unclear. However, it is well established that
both Epo and VEGF are stimulated via HIF-1α during hypoxia,
which then leads to angiogenesis,235,236 therefore timing of
administration may be crucial.
Steroid
In 1992, two conﬂicting retrospective studies were published
regarding the incidence of ROP requiring laser therapy and
postnatal dexamethasone. Batton et al.237 reported that of the
21 factors examined, only the use of steroids was signiﬁcantly
associated with the need for cryotherapy. On the other hand,
Sobel and Philip238 showed a reduction in the need for
cryotherapy with prolonged dexamethasone. Several other
reports conﬁrmed the ﬁndings of Baton et al.237 of an
increased risk of ROP with steroids,239–244 while other studies
showed no association.245–249 However, meta-analyses
showed that early exposure to steroids was not associated
with a risk of severe ROP,250,251 while exposure at 47days252
and43weeks253 caused an increase in severe ROP. The use of
antenatal steroids was associated with signiﬁcantly less stage
2 or higher ROP.93,254 Another study comparing antenatal
betamethasone with antenatal dexamethasone showed a
trend for greater risk of severe ROP associated with dexame-
thasone.255 Due to its association with increased incidence of
cerebral palsy,98 the use of dexamethasone has been
restricted.
Indomethacin
Indomethacin is a nonselective COX inhibitor used in neo-
natology for closure of a patent ductus arteriosus. While
studies found no relationship between indomethacin and
ROP,256,257 one retrospective study of over 34,000 preterm
infants from 162 sites showed a higher incidence of severe
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on the ﬁrst day of life.258 Darlow et al.259 reported that infants
treated with indomethacin were 1.5 times more likely to have
ROP than untreated infants. Another study involving 105
preterm infants o28 weeks gestation who received low
versus high indomethacin showed a signiﬁcant increase in
the incidence of moderate/severe ROP which was directly
related to the indomethacin serum concentrations.260 Con-
versely, a retrospective chart review found that indomethacin
use for PDA was protective for ROP.261 It is suggested that the
contradictory effects of indomethacin on ROP may be related
to the infant’s postnatal age.262 This may indicate that the
exact timing of treatment may be crucial, and further studies
in this regard are needed.Conclusions
ROP is a multifactorial disease, the cause of which remains
largely unknown. Infants at risk suffer from numerous con-
ditions and are exposed to many forms of polypharmacy
which likely add to the etiology of the disease. Since its
appearance in the 1940s, pharmacologic interventions for
treatment and/or prevention of ROP have predominantly
targeted oxidants and VEGF. Furthermore, an overwhelming
majority of human and animal studies have focused on
rescue treatment of ROP when damage to the retina has
already occurred. Given the multifactorial characteristic of
ROP and complexity of the disease, the use of a single
therapeutic agent may not be prudent. No one therapy has
proven to be effective without adverse effects. The timing of
treatment must be considered as it is preferred to prevent
any form of ROP rather than minimize its progression. There
are conﬂicting reports regarding the beneﬁts of many of the
past and current therapies, most of which were initiated
based on anecdotal/observational reports, and in some cases
have resulted in severe adverse events to the detriment of the
treated infant. Therefore, only data from well-designed,
randomized, multicenter, placebo-controlled trials, as well
as long-term follow-up studies should be the criteria for
implementing a change in clinical practice to use off-label
pharmaceuticals in these vulnerable patients.
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